Volk H D, Thieme M, Heym S, Döcke W D, Ruppe U, Tausch W, Manger D, Zuckermann S, Golosubow A, Nieter B
Institute for Medical Immunology.
Behring Inst Mitt. 1991 Feb(88):208-15.
Recently we described the predictive value of the proportion of HLA-DR+ peripheral blood monocytes for the clinical outcome of septic disease in immunosuppressed patients (allograft recipients) and surgical patients mostly with peritonitis as septic focus (following perforation of gastrointestinal tract). The experiments described here show that the loss of HLA-class II antigen expression and other phenotypical abnormalities of monocytes from septic patients with fatal outcome are associated with functional defects (antigen presentation, formation of reactive oxygen species, cytokine secretion). The picture of phenotypical and functional defects of monocytes was termed "immunoparalysis" (leading parameter: loss of HLA-DR antigen expression less than 20%). Interferon-gamma as well as GM-CSF normalized in vitro the surface antigen expression on monocytes derived from septic patients with "immunoparalysis". However, sera from patients with "immunoparalysis" prevented the cytokine-mediated effects on HLA-DR antigen expression. The inhibitory activity in septic sera was not dialysable. In order to remove such factors we started a plasmapheresis study in septic patients selected for "immunoparalysis". The preliminary data of this clinical trial suggest an improved survival rate.
最近,我们描述了HLA - DR +外周血单核细胞比例对免疫抑制患者(同种异体移植受者)和主要以腹膜炎为脓毒症病灶(胃肠道穿孔后)的手术患者脓毒症疾病临床结局的预测价值。此处描述的实验表明,具有致命结局的脓毒症患者单核细胞HLA - II类抗原表达缺失及其他表型异常与功能缺陷(抗原呈递、活性氧生成、细胞因子分泌)相关。单核细胞的表型和功能缺陷情况被称为“免疫麻痹”(主要参数:HLA - DR抗原表达缺失少于20%)。γ干扰素以及粒细胞巨噬细胞集落刺激因子可在体外使来自患有“免疫麻痹”的脓毒症患者的单核细胞表面抗原表达正常化。然而,患有“免疫麻痹”患者的血清会阻止细胞因子对HLA - DR抗原表达的影响。脓毒症血清中的抑制活性不可透析。为了去除此类因素,我们对选定为“免疫麻痹”的脓毒症患者开展了一项血浆置换研究。该临床试验的初步数据表明生存率有所提高。